This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Bristol-Myers Squibb Company (BMY): Health Care's Featured Stock Of The Day

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Bristol-Myers Squibb Company (
BMY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Bristol-Myers Squibb Company rose 41 cents (1%) to $41.19 on average volume. Throughout the day, 10.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10 million shares. The stock ranged in a price between $40.81-$41.25 after having opened the day at $40.95 as compared to the previous trading day's close of $40.78. Other companies within the Health Care sector that increased today were:
Repros Therapeutics (
RPRX), up 76.3%,
InfuSystems Holdings (
INFU), up 11%,
MGC Diagnostics (
MGCD), up 10.9%, and
Affymax (
AFFY), up 10.9%.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $66.83 billion and is part of the drugs industry. The company has a P/E ratio of 35.1, above the S&P 500 P/E ratio of 17.7. Shares are up 25.1% year to date as of the close of trading on Wednesday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a
buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.